

NOV 17 2018

Attachment 1**Explanation for Animals Listed in Category E-APHIS Form 7023: FY 2016**

Registration Number 22-R-0149

Customer number 328985

Dogs

Forty (40) dogs were used in (b) (4) to evaluate the efficacy of novel therapeutic compounds. Reactions in these animals following compound administration were signs that would be expected in respiratory infections, such as coughing, sneezing, mucopurulent ocular and nasal discharge, depression, retching, and weight loss. Pain relieving drugs were not used as they would have adversely affected the scientific validity of the study. The animals remained on study under veterinary oversight.

Guinea pigs

The study objective was to (b) (4)
 (b) (4)
 (b) (4) Six hundred-one (601) animals experienced acute lameness due to localized muscle or tissue damage from the administration of challenge material. Within this group of animals, one hundred thirtyfive (135) also experienced acute systemic toxic effects and were euthanized or died during the study. Use of drugs may invalidate the scientific validity of the results as per CFR regulations.

Hamsters

The study objective was to (b) (4)
 (b) (4)
 (b) (4) One thousand one hundred eighty-nine (1189) experienced acute systemic toxic effects and died during the conduct of the study. Use of drugs may invalidate the scientific validity of the results per CFR regulations.

Horses

In twenty-eight (28) horses, the work (b) (4)
 (b) (4) does not permit (b) (4)
 (b) (4) including the administration of analgesics, systemic symptomatic or therapeutic treatment due to the possible residual contamination of the final blood product, which is used as a human therapeutic.